Vis børsmeldingen
a Swedish-based company specializing in data analytics of diabetes data.
The strategic cooperation will provide Lifecare access to OneTwo’s portfolio
of comprehensive AI and ML based software for self-monitoring and automatic
interpretation of CGM data. Furthermore, OneTwo will act as Lifecare’s digital
development partner on a consultancy base, as Lifecare intends to
commercialize the software tool in the field of veterinary medicine on a
license-base.
This marks a significant milestone in the advancement of veterinary medicine,
aiming to bring cutting-edge analytical software developed for the human
diabetes market to the veterinary field.
Under the terms of the strategic cooperation, OneTwo will leverage its
expertise in data analytics and software development to create a digital
infrastructure tailored to the needs of veterinary professionals. The
centerpiece of this collaboration is OneTwo’s “INSIGHTS and Clinic Portal”
software.
Lifecare will take the lead in commercializing this advanced analytical
software within the global veterinary market. The partnership grants Lifecare
an exclusive, worldwide license to modify, market, and brand the software
under its name. This software is designed to analyze glucose data from CGM
sensors, providing critical insights into glucose deviations and fluctuations,
which are vital for the diagnosis, treatment, and management of diabetes.
As part of the strategic cooperation, OneTwo will also develop a user-friendly
mobile application compatible with both iOS and Android platforms. This app
will facilitate seamless data transmission from the Sencell sensors to cloud
servers and enable bi-directional communication with the customized analytical
software. The digital infrastructure will not only serve the veterinary sector
but also retain compatibility for potential human healthcare applications.
-
Lifecare’s vision has always been to make glucose monitoring easier for the
patient using our Sencell sensor. In order to meet that customer promise, we
must also be able to easily provide insight into valuable diabetes data
through innovative and user-friendly software solutions, says Joacim Holter,
CEO of Lifecare.
-
We are thrilled to partner with OneTwo. This partnership underlines our
commitment to promoting innovative technological solutions within diabetes
monitoring and improving the health and well-being of patients worldwide, says
Holter.
-
Continuous monitoring of glucose levels entail large amounts of data for the
clinicians and patients to interpret. Implementing AI/ML-based software to
exploit and understand the amount of data is an absolute necessity. OneTwo’s
products are cutting edge, and this represents a significant strategic
opportunity for us to introduce this, also in the veterinary market. In
addition, we follow our overall strategy by introducing a uniform system that
positions us for a later market launch in the human market, says Holter.
-
This partnership is a natural extension of our mission to harness the power
of data analytics for better health outcomes. By combining our technological
expertise with Lifecare’s market potential, we are poised to make a
significant impact in both veterinary and human healthcare, says Lars
Cederblad, co-founder and CEO of OneTwo Analytics AB.
OneTwo’s development is rooted in scientific research by endocrinologists from
Uppsala University and co-founders of OneTwo, Per-Ola Carlsson (MD, PhD,
Professor) and Daniel Espes (MD, PhD, Assoc. Professor). The Swedish company’s
software is in compliance with the European Medical Device Directive/Medical
Device Regulations and ISO 13485 and approved by the FDA for the US market.
OneTwo’s software is implemented in Swedish and US health care clinics
ensuring automated interpretation of CGM data. The software is compatible for
automated interpretation of the CGM marked leaders Abbott and Dexcom sensors,
of which OneTwo are engaged in a partnership with Dexcom for the Nordic and US
market.
The parties have signed a Heads of Terms describing the strategic cooperation
and will work closely together to finalize the agreement.
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-08-13 07:00 CEST.
Kilde
